These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12463072)

  • 21. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation.
    Divecha H; Sattar N; Rumley A; Cherry L; Lowe GD; Sturrock R
    Clin Sci (Lond); 2005 Aug; 109(2):171-6. PubMed ID: 15801904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of emerging risk factors for therapeutic intervention.
    Assmann G; Cullen P; Fruchart JC; Greten H; Naruszewicz M; Olsson A; Paoletti R; Riesen W; Stoll M; Tikkanen M; von Eckardstein A;
    Nutr Metab Cardiovasc Dis; 2005 Oct; 15(5):373-81. PubMed ID: 16216724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
    Packard C
    Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is C-reactive protein an important marker for coronary events?
    Manag Care Interface; 2005 Feb; 18(2):19-20, 30. PubMed ID: 15766060
    [No Abstract]   [Full Text] [Related]  

  • 28. [C-reactive protein in cardiovascular diseases].
    Lubas W; Gutkowski K
    Przegl Lek; 2006; 63(7):562-6. PubMed ID: 17203810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of hs-CRP measurements in the current cardiovascular risk assessment.
    García-Moll X; Ordóñez-Llanos J
    Clin Chim Acta; 2005 May; 355(1-2):215-8. PubMed ID: 15820499
    [No Abstract]   [Full Text] [Related]  

  • 30. C-reactive protein and coronary heart disease.
    Foody JM; Gotto AM; Wenger N
    N Engl J Med; 2004 Jul; 351(3):295-8; author reply 295-8. PubMed ID: 15257565
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation.
    Tam LS; Tomlinson B; Chu TT; Li M; Leung YY; Kwok LW; Li TK; Yu T; Zhu YE; Wong KC; Kun EW; Li EK
    Rheumatology (Oxford); 2008 May; 47(5):718-23. PubMed ID: 18400833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [C-reactive protein: cardiovascular issues of an acute-phase protein].
    Amezcua-Guerra LM; Springall del Villar R; Bojalil Parra R
    Arch Cardiol Mex; 2007; 77(1):58-66. PubMed ID: 17500194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-reactive protein, cardiovascular disease and stroke: new roles for an old biomarker.
    Willcox BJ; Abbott RD; Yano K; Rodriguez BL; Willcox DC; Curb JD
    Expert Rev Neurother; 2004 May; 4(3):507-18. PubMed ID: 15853546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
    Couzin J
    Science; 2008 Nov; 322(5904):1039. PubMed ID: 19008423
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin.
    May A; Wang TJ
    Expert Rev Mol Diagn; 2007 Nov; 7(6):793-804. PubMed ID: 18020909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Family history of diabetes or cardiovascular disease and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey, 1999-2000.
    Ford ES; Giles WH; Mokdad AH
    Am J Prev Med; 2005 Dec; 29(5 Suppl 1):57-62. PubMed ID: 16389127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein.
    Chasman DI; Kozlowski P; Zee RY; Kwiatkowski DJ; Ridker PM
    Genes Immun; 2006 Apr; 7(3):211-9. PubMed ID: 16511556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum lipids and neopterin in urine as new biomarkers of malnutrition and inflammation in the elderly.
    Hrnciarikova D; Hyspler R; Vyroubal P; Klemera P; Hronek M; Zadak Z
    Nutrition; 2009 Mar; 25(3):303-8. PubMed ID: 19019628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?
    Blankenberg S; Yusuf S
    Circulation; 2006 Oct; 114(15):1557-60. PubMed ID: 17030701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.